BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 11253769)

  • 1. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
    Bunnag P; Puavilai G; Chanprasertyotin S; Chandraprasert S; Suwanwalaikorn S; Suthijumroon A; Benjasuratwong Y; Boonyavarakul A; Nitiyanant W; Sriussadaporn S; Deerochanawong C;
    Diabetes Res Clin Pract; 2001 Feb; 51(2):151-3. PubMed ID: 11253769
    [No Abstract]   [Full Text] [Related]  

  • 2. [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
    Ohmura E; Hosaka D; Imai Y; Kawazu S
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():470-5. PubMed ID: 12387036
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
    Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
    Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.
    Horton ES; Whitehouse F; Ghazzi MN; Venable TC; Whitcomb RW
    Diabetes Care; 1998 Sep; 21(9):1462-9. PubMed ID: 9727892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
    Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.
    Gavin LA; Barth J; Arnold D; Shaw R
    Endocr Pract; 2000; 6(4):305-10. PubMed ID: 11242607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
    Hershon KS; Hershon PM
    Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using dose-response characteristics of therapeutics agents for treatment decisions in type 2 diabetes.
    Garber AJ
    Diabetes Obes Metab; 2000 Jun; 2(3):139-47. PubMed ID: 11220549
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients.
    Fonseca V; Foyt HL; Shen K; Whitcomb R
    Diabetes Care; 2000 Mar; 23(3):354-9. PubMed ID: 10868865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deterioration of glycemic control after long-term treatment with troglitazone in nonobese type 2 diabetic patients.
    Murase Y; Wakasugi T; Yagi K; Mabuchi H
    Diabetes Care; 2000 Jan; 23(1):131-2. PubMed ID: 10857989
    [No Abstract]   [Full Text] [Related]  

  • 11. International Diabetes Federation meeting, 1997. Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone.
    Bloomgarden ZT
    Diabetes Care; 1998 Jun; 21(6):1024-6. PubMed ID: 9614626
    [No Abstract]   [Full Text] [Related]  

  • 12. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.
    Iwatani M; Wasada T; Katsumori K; Watanabe-Takahashi C; Kamatani N; Iwamoto Y
    Diabetologia; 2000 Jun; 43(6):814-5. PubMed ID: 10907128
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of troglitazone in type 2 diabetes mellitus.
    Gorson DM
    N Engl J Med; 1998 Aug; 339(6):406. PubMed ID: 9696655
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of troglitazone in type 2 diabetes mellitus.
    Rusk MH
    N Engl J Med; 1998 Aug; 339(6):406. PubMed ID: 9696656
    [No Abstract]   [Full Text] [Related]  

  • 15. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes.
    Katsuki A; Sumida Y; Murata K; Furuta M; Araki-Sasaki R; Tsuchihashi K; Hori Y; Yano Y; Gabazza EC; Adachi Y
    Diabetes Obes Metab; 2000 Jun; 2(3):189-91. PubMed ID: 11220554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
    Imano E; Kanda T; Nakatani Y; Nishida T; Arai K; Motomura M; Kajimoto Y; Yamasaki Y; Hori M
    Diabetes Care; 1998 Dec; 21(12):2135-9. PubMed ID: 9839106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of troglitazone on body fat distribution in type 2 diabetes.
    Akazawa S; Sun F; Ito M; Kawasaki E; Eguchi K
    Diabetes Care; 2000 Aug; 23(8):1067-71. PubMed ID: 10937499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.
    Ghazzi MN; Perez JE; Antonucci TK; Driscoll JH; Huang SM; Faja BW; Whitcomb RW
    Diabetes; 1997 Mar; 46(3):433-9. PubMed ID: 9032099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
    Blonde L; Sandberg MI; Guthrie RD
    Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262
    [No Abstract]   [Full Text] [Related]  

  • 20. Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial.
    Katoh S; Hata S; Matsushima M; Ikemoto S; Inoue Y; Yokoyama J; Tajima N
    Metabolism; 2001 Apr; 50(4):414-7. PubMed ID: 11288035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.